Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications

Diabetes Care

Volumn 22, Issue SUPPL. 2, 1999, Pages

  Friedman, Eli A ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; AMINOGUANIDINE; OLIGOPEPTIDE 9195; PROTEIN KINASE C; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; NONHUMAN;

EID: 0032971837     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Mauer SM, Chavers BM: A comparison of kidney disease in type I and type II diabetes. Adv Exp Med Biol 189:299-303, 1985
2. U.S. Renal Data System: USRDS 1997 Annual Data Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1997
3. Wang PH, Korc M: Searching for the Holy Grail: the cause of diabetes (Letter). Lancet 346:s4, 1995
4. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SEM: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 45:179-188, 1994
5. Porte Jr. D, Schwartz MW: Diabetes complications: why is glucose potentially toxic? Science 272:699-670, 1996
6. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
7. Craven PA, Studer RK, Negrete H, DeRubertis FR: Protein kinase C in diabetic nephropathy. J Diabetes Complications 9:241-245, 1995
8. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform bII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility in glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
9. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 87:31-38, 1989
10. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265:E783-E793, 1993
11. Wolf BA, Williamson JR, Eamon RA, Chang K, Sherman WR, Turk J: Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 87:31-38, 1991
12. Kikkawa HM, Sugimoto T, Koya D, Araki S, Togawa M, Shigeta Y: Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications 9:246-248, 1995
13. Ziyadeh FN, Fumo P, Rodenberger CH, Kuncio GS, Neilson EG: Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1(IV) in glomerular mesangial cells. J Diabetes Complications 4:255-261, 1995
14. 2 inhibitor. Science 272:728-731, 1996
15. Frank RN: The aldose reductase controversy Diabetes 43:169-172, 1994
16. Van Heyningen R: Formation of polyols by the lens of the rat with "sugar" cataract. Nature 184:194-195, 1959
17. Tomlinson DR, Stevens EJ, Diemel LT: Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci 15:293-297, 1994
18. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T: High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 37:328-330, 1994
19. Brownlee M: Glycation and diabetic complications. Diabetes 43:837-841, 1994
20. Vlassara H: Protein glycation in the kidney: role in diabetes and aging. Kidney Int 49:1795-1804, 1996
21. Kato H, Hayase F, Shin DB, Oimomi M, Baba S: 3-Deoxyglucosone, an intermediate product of the Maillard reaction. Prog Clin Biol Res 304:69-84, 1989
22. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878, 1995
23. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunte M, Verger C, Jungers P, Descamps-Latscha B: The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 45:379-382, 1996
24. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link From human extracellular matrix. J Biol Chem 264:21597-21602, 1989
25. Niwa T, Kaatsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
26. Schleicher ED, Wagner E, Nerlich AG: Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:3:457-468, 1997
27. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 96:1395-1403, 1995
28. Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, Zhao L, Schmidt AM, Scherrmann JM, Wautier JL: Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 52:54-62, 1997
29. Koschinsky T, He CJ, Mitsuhashi T, Cucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Proc Natl Acad Sci U S A 94:6474-6479, 1997
30. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals, a model for diabetic and aging complications. Proc Natl Acad Sci U S A 89:12043-12047, 1992
31. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436-9440, 1994
32. Vlassara H: Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif 12:54-59, 1994
33. Bucala R: What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Res Clin Pract 30 (Suppl.):123-130, 1996
34. Basta, G, DeCaterina R: Products of advanced glycosylation and the pathogenesis of accelerated atherosclerosis in diabetes. G Ital Cardiol 26:699-719, 1996
35. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency Proc Natl Acad Sci U S A 91:9441-9445, 1994
36. Tanaka, S, Avigad, G, Brodsky, B, Eikenberry, EF: Glycation induces expansion of the molecular packing of collagen. J Mol Biol 203:495-505, 1988
37. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R: Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656, 1993
38. Tsilibary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT: The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem 263:4302-4308, 1988
39. Way KJ, Reid JJ: Effect of aminoguanidine on the impaired nitric oxide-mediated neurotransmission in anococcygeum muscle from diabetic rats. Neuropharmacology 33:1315-1322, 1994
40. Knowx LK, Stewart AG, Hayward PG, Morrison WA: Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery 15:708-711, 1994
41. Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Cora NS, Kaplan HJ, Williamson JR: Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 35:3278-3288, 1994
42. Hogan M, Cerami A, Bucala R: Advanced glycosylation end products block the antiproliferative effect of nitric oxide: role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90:1110-1105, 1992
43. Brownlee M, Vlassara H, Kooney T, Ulrich P Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
44. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558, 1991
45. Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93:1905-1912, 1996
46. Swamy-Mruthinti S, Green K, Abraham EC: Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp Eye Res 62:505-510, 1996
47. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
48. Soulis, T, Cooper, ME, Vranes, D, Bucala R, Jerums G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634, 1996
49. Cohen MP, Hud E, Wu VY: Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int 45:1673-1679, 1994
50. Miyauchi Y, Shikama H, Takasu T, Okamiya H, Umeda M, Hirasaki E, Ohhata I, Nakayama H, Nakagawa S: Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats. European J Endocrinol 134:467-473, 1996
51. Archibald V, Cotter MA, Keegan A, Cameron NE: Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn Schmiedbergs Arch Pharmacol 353:584-591, 1996
52. Brownlee M: Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 304:235-248, 1989
53. Sensi M, Pricci F, Andreani D, DiMario U: Advanced nonenzymatic glycation end products (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 16:1-9, 1991
54. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
55. Corbett JA, Tilton RG, Chang K: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
56. Cameron NE, Cotter MA: Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. Metabolism 45:1147-1152, 1996
57. Hogan M, Cerami A, Bucala R: Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide: role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90:1110-1115, 1992
58. Kone BC, Baylis C: Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 272 (5 Pt 2):F561-F578, 1997
59. Booth AA, Khalifah RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): novel inhibition of post-Amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
60. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
61. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 138:1886-1892, 1997
62. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278, 1996